Pediatrics · 2026
Thyroid Monitoring After Intravascular Iodinated Contrast Media in Infants and Children Through 3 Years of Age.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Miller Ryan S, Dillman Jonathan R, Crystal Matthew A, Bethin Kathleen, Dinauer Catherine A, Forbes-Amrein Monica, Gordon Brent M, Hughes Bridget, Lahoti Amit, Marshall Audrey C, Mastrandrea Lucy D, Pesce Liuska M, Rapaport Robert, Salavitabar Arash, Wasserman Jonathan D, Bauer Andrew J, Wassner Ari J
Аннотация
In March 2022, the US Food and Drug Administration issued a drug safety communication (DSC) recommending monitoring of thyroid function in children up to 3 years of age who receive intravascular injection of iodinated contrast media (IV ICM) for medical imaging. In response, a group of pediatric and imaging experts convened to review the current scientific evidence on thyroid dysfunction after IV ICM and to provide recommendations on thyroid testing and management after IV ICM administration in infants and children. There are considerable gaps in knowledge related to the risk of thyroid dysfunction in young children exposed to IV ICM, and we strongly recommend that high-quality prospective studies be proposed and funded to clarify the incidence, risk modifiers, natural history, and outcomes of thyroid dysfunction after IV ICM exposure in this population.